[stock_market_widget type=”card” template=”basic2″ assets=”TNXP” realtime=”true” api=”yahoo-finance”]
Fibromyalgia is a chronic pain condition that has puzzled doctors for decades. It brings widespread aches across the body, along with deep fatigue, broken sleep, and a mental cloudiness that many patients call fibro fog. The condition affects an estimated 10 million people in the United States, and the large majority of them are women. It is not an inflammatory or autoimmune disease, and routine scans and blood tests usually come back normal, which can make it slow to diagnose and easy to dismiss. Researchers now see it less as damage in the muscles and more as a problem in how the nervous system handles pain, turning ordinary signals up far louder than they should be.
That uncertainty about the cause helps explain why treatment has been so hard. Symptoms vary widely from one person to the next, and relief has long been hit or miss. For years only three medicines carried FDA approval for the condition: pregabalin, duloxetine, and milnacipran, all cleared between 2007 and 2009. None were designed for fibromyalgia. They were built to treat seizures or depression and later repurposed, and many patients find them either weak or hard to tolerate. Sleep sits near the center of the problem, because poor rest tends to worsen pain and mood while pain in turn wrecks sleep, feeding a cycle that is difficult to break. That long stretch without a fresh option is the backdrop for a small New Jersey drugmaker now trying to prove it can sell one.
Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) is a commercial-stage biopharmaceutical company based in Berkeley Heights, New Jersey. Its flagship product, TONMYA, is a non-opioid tablet that dissolves under the tongue and is taken at bedtime by adults with fibromyalgia. Its selling point is timing, because it is the first medicine the U.S. Food and Drug Administration has cleared for the condition in more than fifteen years, and unlike the older drugs it was created specifically for it. It also sells two migraine treatments and has a pipeline reaching into depression and infectious disease.
The company drew notice in early August for a single figure. In the three months that ended in June, sales of TONMYA reached roughly $11.0 million, nearly triple the prior quarter. The growth showed up across the measures that matter most early in a launch: total prescriptions doubled to about 12,592, refills climbed 207%, and new patient prescriptions rose 36%. For a product that only reached pharmacies in November 2025, a jump of that size suggests early users are sticking with it. The count even includes short bridge supplies handed out while insurance is still being sorted out.
Getting a drug prescribed and getting it paid for are separate battles, and much of the recent progress traces back to insurance. After deals with two large purchasing groups in the spring, TONMYA was covered for about 136 million people across commercial, Medicare, and Medicaid plans by the end of June, close to 43% of insured lives nationwide. Still, the company is not profitable. It posted a net loss of about $40.6 million for the quarter while holding roughly $176.2 million in cash, enough by its own estimate to last into early 2027, and total product revenue including the migraine drugs came to about $13.5 million, up from $2.0 million a year earlier.
Beyond fibromyalgia, the company is working to widen the uses of the same core molecule. In June it enrolled the first patient in a study called HORIZON, a mid-stage trial testing the compound against major depression rather than pain. Tonix is also developing an antibody meant to prevent Lyme disease, with a field study expected in early 2027. These programs sit years from any payoff, yet they hint at the ambition underneath the launch.
What the second quarter really measured was whether a rare approval could turn into steady demand, and the early answer looks encouraging. A near tripling of sales in three months is the kind of move that gets noticed, though the story is far from settled. The months ahead will show whether the pace holds once the newest sales staff are working and the coverage gains fully reach patients.
